<?xml version="1.0" encoding="UTF-8"?>
<p>For a subset of 35 patients (
 <bold>
  <xref ref-type="fig" rid="pone.0230337.g004">Fig 4A</xref>
 </bold>), a follow-up sample (“S2”) could be obtained in the convalescent phase of the disease (median day 20 post onset of symptoms). While all S2 samples were tested positive in the Panbio IgM ELISA, only 22/35 (62.9%) of samples were detected as DENV IgM positive in the SD Bioline Dengue Duo IgM test (
 <bold>
  <xref ref-type="fig" rid="pone.0230337.g004">Fig 4B</xref>
 </bold>). A significant difference was observed between patients with a different anti-DENV IgG status of S1 samples (
 <bold>
  <xref ref-type="fig" rid="pone.0230337.g004">Fig 4E</xref>
 </bold>): IgM antibodies were detectable in the S2 sample by the SD Bioline Dengue Duo IgM test in 11/11 (100.0%) of patients with an DENV IgG IIFT negative S1 sample (
 <bold>
  <xref ref-type="fig" rid="pone.0230337.g004">Fig 4C</xref>
 </bold>), but only in 11/24 (45.8%) of patients with an DENV IgG IIFT IgG positive S1 sample (
 <bold>
  <xref ref-type="fig" rid="pone.0230337.g004">Fig 4D</xref>
 </bold>).
</p>
